The AI-native operating system for the drug lifecycle.
The whole pharma value chain on a single, HAIOps-governed AI engine. One engine you build once and reuse everywhere; a defensible in-silico wedge that predicts what your lab will measure; and a spine of products that spans discovery through care.
Three layers, one platform.
Not a suite of tools stitched together. A single engine, a defensible wedge, and the product surfaces that sit on top of both. Read it from the foundation up.
One core engine
Hakase is not a suite of tools stitched together. Every module runs on a single core engine — sharing one orchestration layer and one RAG flywheel — with every output passed through an evidence gate and cross-cutting audit and evaluation before it reaches a user.
Inputs are drawn from public sources. We never read, store, or use your proprietary data to train models for anyone else.
That's the moat: full tenant isolation, enforced by architecture.
The operating layer for safe, traceable, clinically-governed AI.
HAIOps extends traditional MLOps with clinical validation, patient-safety oversight, regulatory traceability, and operational governance for healthcare AI systems.
Built for a regulated industry.
Every advancement is gated, every claim is provenance-tracked, and privacy holds by construction — so in-silico evidence can be presented in the language regulators already use.
Purpose-built layers on one core engine.
On the shared engine, the products stop looking like scatter and start looking like coverage — one stage feeding the next, from first signal to the clinic, the label, and back to the bedside. These are the internal R&D and conversational surfaces — aktiv8, the market-facing intelligence layer, spans the whole lifecycle and gets its own section below.
aktiv8 — the intelligence layer for everyone around the science.
aktiv8 is a Life Sciences Intelligence & Connection Platform. It identifies, tracks and contextualises activity across the entire ecosystem — and connects the right stakeholders to act on it, regardless of role.
It doesn't manage the science itself. It gives everyone around it — investors, BD teams, CROs, CDMOs, banks, advisors, vendors — the intelligence to find opportunities and reach the right counterpart at exactly the right moment.
The signal-to-connection platform for life sciences — it monitors every company, asset, catalyst, trial, funding event and regulatory milestone across the lifecycle, and connects the right people to act, with verified contacts and AI-drafted outreach, before the opportunity is widely known.
What the platform does in practice.
Real engagements on the shared engine — cross-stage synthesis that would take a human analyst weeks, delivered in a session.
Case studies describe real engagements and shipped capabilities. Quantitative outcomes per engagement available under NDA.
Decision-analytics-as-a-service.
Delivered as outcomes, not seats — priced to the unit of value you actually buy.
One platform for the entire drug lifecycle.
Discovery through care, on a single HAIOps-governed engine — built once, and reused across every stage. That's the moat, the wedge, and the spine of products, together.